In 2009, affected by the international financial crisis and the appreciation of the renminbi, the volume of raw material medicine exports in China declined. According to statistics of Huicong Dengbai's medical research, the export quantity of penicillin raw materials in China from January to February 2010 was 3,558 tons. Compared with the export volume of 3,603 tons in January-February 2009, the export volume decreased by 1.2%. The number of exports did not gradually recover in 2010 as predicted earlier.
From the perspective of the structure of export products, the export quantity of penicillin G in China continues to decline, and this downward trend will be more pronounced in the second half of the year, while the export volume of 6-APA (6-aminopenicillanic acid) will appear to be relatively small. Fast growth. Industry experts predict that 6-APA will be affected by the increasing demand in the international market, and the number of exports in the latter period will maintain rapid growth.
2009 (1-2)-2010 (1-2) months raw material drug penicillin exports
Unit: tons
The production capacity of penicillin raw materials has been in a state of surplus in the domestic market. In the face of international market sales, competition in the domestic market has intensified, and various companies have adopted countermeasures to objectively promote the adjustment of the product structure of the industry and the pace of technological upgrading. The following is a brief analysis of the production situation and measures taken by major manufacturers of penicillin bulk drugs in China from January to February 2010.
Table. Yields of major manufacturers of penicillin bulk drugs in China in January-February 2010
company name
Production in January-February 2009 (t)
Compared to the same period
Shijia Group Hebei Zhongrun Pharmaceutical
220
Flat
Zhuhai federal pharmaceutical
200
slightly increased
Harbin Pharmaceutical Group Pharmaceutical Factory
180
Flat
Henan Xinxiang Huaxing Pharmaceutical Factory
150
Compression 3/5 capacity
North China Pharmaceutical
120
decline
total
870
/
Source: Huicong Deng Baishi Research
As can be seen from the table, with the traditional penicillin G salt production enterprises, the output has steadily declined. The production of production enterprises based on 6-APA products has increased steadily. In addition to market demand, this change is also an adjustment made by the company based on changes in the market. Faced with the actual market demand, the adjustments made by the penicillin G API manufacturers can be summarized as follows.
1. Improve the technological content of products
According to the personnel of marketing department of Harbin Pharmaceutical Group, the total production and sales of penicillin raw materials in 2010 was basically the same as in the same period of previous years. The number of exports in previous years was 70%; the number of domestic sales accounted for 30%. This year, after increasing the technological content of products, The number of domestic sales has gradually increased, which can account for 50% of the current sales volume of the company; while the impact of the international financial crisis has basically faded, but due to the increase in the number of 6-APA in the international market to replace penicillin G, the export of penicillin G this year has been exported. The number has declined, and the industry expects that this is only at the beginning of the year and that the decline in export volume is not yet obvious. It is expected that this downward trend will become more apparent.
2. Turn to cephalosporin products
In 2008, out of the total business income of more than RMB 6 billion in North China Pharmaceutical, the proportion of sales revenue of antibiotics accounted for nearly 70%. Since the profit of penicillin has been very low (the ex-factory price of a penicillin is less than one dollar), the proportion of lower value-added antibiotics is too large, which has caused the profit of North China Pharmaceuticals to be less than that of some small enterprises. At this point, the penicillin halo that North China Pharmaceutical once proudly lost completely disappeared, and the “base stone†became a “bottleneckâ€. In order to overcome this bottleneck, Wang Sheping, the new chairman of North China Pharmaceuticals, disclosed on November 10 that the cephalosporin project with an initial investment of 2 billion yuan was started on October 18. It will be completed within one year and the estimated new production value is 8 billion yuan. North China Pharmaceuticals will switch from producing penicillin to cephalosporin, and sales revenue will reach 10 billion yuan in 2011.
3. Compress the production of low-end products and increase the output of downstream products in the industrial chain
Facing the weakening demand for penicillin G products in the international market and the upgrading of products in the domestic market, the demand for penicillin G in China gradually decreases, while the 6-APA product downstream of penicillin G salt will gradually increase, and the domestic new medical reform policy will be promoted. With the increase in the demand for products in the international market, it is expected that there will be a rapid increase in China's production capacity of 6-PAP.
Rapid Test Antibody,Antibodies Rapid Test,Antibody Rapid Test Kit,Antibody Rapid Diagnostic Test
